Literature DB >> 26359936

Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension?

Han-Mou Tsai1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26359936      PMCID： PMC8031585          DOI： 10.1111/jch.12664

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  10 in total

1.  Renal proliferative arteriopathies and associated glomerular changes: a light and electron microscopic study.

Authors:  R A Sinclair; T T Antonovych; F K Mostofi
Journal:  Hum Pathol       Date:  1976-09       Impact factor: 3.466

2.  Microangiopathic hemolysis and renal failure in malignant hypertension.

Authors:  Bert Jan H van den Born; Uwkje P F Honnebier; Richard P Koopmans; Gert A van Montfrans
Journal:  Hypertension       Date:  2004-12-13       Impact factor: 10.190

3.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 4.  A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.

Authors:  Han-Mou Tsai
Journal:  Transfus Med Rev       Date:  2014-09-03

5.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

6.  Recovery in malignant hypertension presenting as acute renal failure.

Authors:  C G Isles; A McLay; J M Jones
Journal:  Q J Med       Date:  1984

7.  Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

Authors:  Véronique Fremeaux-Bacchi; Fadi Fakhouri; Arnaud Garnier; Frank Bienaimé; Marie-Agnès Dragon-Durey; Stéphanie Ngo; Bruno Moulin; Aude Servais; François Provot; Lionel Rostaing; Stéphane Burtey; Patrick Niaudet; Georges Deschênes; Yvon Lebranchu; Julien Zuber; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-10       Impact factor: 8.237

8.  Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome.

Authors:  Han-Mou Tsai; Elizabeth Kuo
Journal:  Adv Hematol       Date:  2014-10-22

9.  Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study.

Authors:  Fouad Amraoui; Niels V Van Der Hoeven; Irene G M Van Valkengoed; Liffert Vogt; Bert-Jan H Van Den Born
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-12-27       Impact factor: 3.738

10.  Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study.

Authors:  Fouad Amraoui; Sarah Bos; Liffert Vogt; Bert-Jan van den Born
Journal:  BMC Nephrol       Date:  2012-07-30       Impact factor: 2.388
  10 in total
  3 in total

1.  Complement Activation and Thrombotic Microangiopathies.

Authors:  Marta Palomo; Miquel Blasco; Patricia Molina; Miquel Lozano; Manuel Praga; Sergi Torramade-Moix; Julia Martinez-Sanchez; Joan Cid; Gines Escolar; Enric Carreras; Cristina Paules; Fatima Crispi; Luis F Quintana; Esteban Poch; Lida Rodas; Emma Goma; Johann Morelle; Mario Espinosa; Enrique Morales; Ana Avila; Virginia Cabello; Gema Ariceta; Sara Chocron; Joaquin Manrique; Xoana Barros; Nadia Martin; Ana Huerta; Gloria M Fraga-Rodriguez; Mercedes Cao; Marisa Martin; Ana Maria Romera; Francesc Moreso; Anna Manonelles; Eduard Gratacos; Arturo Pereira; Josep M Campistol; Maribel Diaz-Ricart
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-06       Impact factor: 8.237

Review 2.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

Review 3.  Complement in Secondary Thrombotic Microangiopathy.

Authors:  Lilian Monteiro Pereira Palma; Meera Sridharan; Sanjeev Sethi
Journal:  Kidney Int Rep       Date:  2020-10-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.